Abstracts tagged "colchicine and gout"

Abstract Number: 216 • 2016 ACR/ARHP Annual Meeting
Colchicine Prescribing As a Parameter for QA/QI Process in Gout Care
Peter A. Valen¹, Maren Mahowald², Anne Westgard³, Melissa Atwood^4,5 and Hollis Krug⁶, ¹Rheumatology/ Dept of Medicine, Minneapolis VA and Univ MN Med School, Minneapolis, MN, ²Rheumatology/ Dept of Medicine, Minneapolis VA and Univ MN Med School, SAINT PAUL, MN, ³Rheumatology, VA Med Center MPLS, Minneapolis, MN, ⁴Medicine, Minneapolis VA Health Care System, Minneapolis, MN, ⁵Pharmacy, Minneapolis VA HCS, Minneapolis, MN, ⁶Medicine, Minneapolis VA and Univ MN Med School, Minneapolis, MN
Background/Purpose: Because of the large increase in the price of colchicine with the FDA granted market exclusivity the Pharmacy at the Mpls VA HCS asked…
Abstract Number: 232 • 2016 ACR/ARHP Annual Meeting
Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study
Talia Igel^1,2, Aaron Garza Romero², Virginia Pike³, Stuart Katz⁴, Binita Shah⁵, Irina Dektiarev⁴, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Monash University School of Medicine, Melbourne, Australia, ²Medicine/Rheumatology, NYU School of Medicine, New York, NY, ³Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁴Medicine/Cardiology, NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Division of Cardiology, New York, NY, ⁶Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: To date, most studies of gout and cardiovascular disease have been cross-sectional or retrospective, and have addressed the outcome of acute coronary syndromes. Less…
Abstract Number: 116 • 2015 ACR/ARHP Annual Meeting
The Effect of the Formal Approval of Colchicine on Utilization of Emergency Department and Rheumatology Outpatient Services By Patients with Gout
Leah Krull^1,2, Erin Patton^3,4 and Harry D. Fischer^5,6, ¹Internal Medicine, Mount Sinai Beth Israel, New York, NY, ²Medicine, Mount Sinai Icahn School of Medicine, New York, NY, ³Rheumatology, Mount Sinai Icahn School of Medicine, New York, NY, ⁴Medicine/Rheumatology, Mount Sinai Beth Israel, New York, NY, ⁵Division of Rheumatology, Mount Sinai Beth Israel, New York, NY, ⁶Medicine/Rheumatology, Mount Sinai Icahn School of Medicine, New York, NY
Background/Purpose: Although colchicine has been used in the management of gout for decades, it had never undergone the formal approval process by the Food and…
Abstract Number: 170 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases
Jasvinder A. Singh¹, Shuo Yang² and Jeff Foster³, ¹University of Alabama and VA Medical Center, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Dermatologic side effects to use of gout treatments are concerning to patients. The goal of the study was to assess the risk of occurrence…
Abstract Number: 156 • 2014 ACR/ARHP Annual Meeting
Colchicine and the Risk of Acute Cardiovascular (CV) Events Among Gout Patients: The New York Department of Veterans Affairs Retrospective Cohort Study
Daria B. Crittenden^1,2, Jessica N. Kimmel^1,2, Virginia C. Pike^1,2, Rebecca Boas^1,2, Daniel Diaz^1,2, Cilian J. White^1,2, Michael DeBerardine^1,2, Grace Kim^1,2, Pajazit Morina^1,2, Avni Shah^1,2, Binita Shah^2,3, Steven P. Sedlis^2,3, Jeffrey D. Greenberg^2,4, Craig T. Tenner^2,5, Christopher J. Swearingen^1,6, Svetlana Krasnokutsky Samuels^1,2, Bruce N. Cronstein¹ and Michael H. Pillinger^1,2, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²VA New York Harbor Health Care System, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Department of Medicine, New York, NY, ⁶Department of Pediatrics and Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
Background/Purpose: Gout patients are at increased risk for CV disease, possibly owing to chronic inflammation. Colchicine is commonly used in gout, and inhibits inflammatory cell…
Abstract Number: 165 • 2012 ACR/ARHP Annual Meeting
Colchicine Is Associated with a Decreased Rate of Myocardial Infarction in Gout Patients: Interim Results From a Retrospective Cohort Study
Daria B. Crittenden¹, Cilian J. White¹, Michael DeBerardine¹, Grace Kim², Binita Shah³, Jessica C. Kimmel¹, Rima D. Patel¹, Steven P. Sedlis³, Jeffrey D. Greenberg⁴, Craig T. Tenner⁵, Bruce N. Cronstein¹ and Michael H. Pillinger¹, ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁵Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY
Background/Purpose: Atherosclerosis is an inflammatory process, but to date no anti-inflammatory agent has definitively been shown to alter cardiovascular (CV) risk. Colchicine is an anti-inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].